Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A1EWVY8
Thu, 25.04.2024
Formycon AG
Press release // April 25, 2024
Formycon reports audited annual results for the financial year 2023 – Looking back on a successful operative year and exceeded guidance
Preliminary results 2023 confirmed
Group revenue increases by 83% compared to the previous year to a total of € 77.7 million
Positive Group EBITDA of around € 1.5 million and adj [ … ]
Mon, 22.04.2024
Formycon AG
Press Release // April 22, 2024
Formycon invites to the conference call on the results of the financial year 2023 and announces participation in international investor conferences in the 2nd quarter of 2024
Munich - Formycon AG (FWB: FYB, 'Formycon') today announced details of the conference call to release the results of the financial year 2 [ … ]
Fri, 12.04.2024
Formycon AG
Press release // 12 April 2024
Convincing overall performance - Formycon reports preliminary results for the financial year 2023 and exceeds forecast
Group revenue increase by 83% compared to the previous year to a total of € 77.7 million
Positive Group EBITDA of around € 1.5 million achieved
New key financial performance indicator (KPI) " [ … ]
Fri, 12.04.2024
Formycon AG
Disclosure of inside information according to Article 17 of the Regulation (EU) No 596/2014
Formycon AG publishes preliminary figures for the 2023 financial year and guidance for the 2024 financial year
Planegg-Martinsried, Germany, 12. April 2024 – Based on preliminary and unaudited figures for the 2023 financial year, Formycon AG (ISIN: DE000A1 [ … ]
Thu, 11.04.2024
Formycon AG
Press release // April 11, 2024
Formycon announces commercial launch of FYB201 (Ranibizumab) in Canada (RanoptoTM) and Switzerland (Ranivisio®)
Commercial launch opens up additional key markets in Europe and North America, making FYB201 available in a total of 17 countries worldwide
Lucentis® biosimilar FYB201 is an effective and cost-effi [ … ]
Mon, 18.03.2024
Formycon AG
Press release // March 18, 2024
Formycon and Fresenius Kabi reach settlement agreement for ustekinumab biosimilar candidate FYB202 in Europe and Canada
Munich, Germany – Formycon AG (FSE: FYB) and its commercialization partner Fresenius Kabi today announced the signing of a settlement agreement with Johnson & Johnson concerning the comme [ … ]
Mon, 11.03.2024
Formycon AG
Press release // March 11, 2024
FYB201/Ranibizumab keeps gaining momentum with approvals and launches in the MENA region
Commercialization partner MS Pharma wins government tender for Ranibizumab in Saudi Arabia
Commercial launch of FYB201/Ravegza® planned for second quarter of 2024
Further launches planned throughout 2024 to improve access [ … ]
Mon, 29.01.2024
Formycon AG
Press Release // January 29, 2024
Gedeon Richter becomes strategic investor of Formycon via equity investment
Already established trustful collaboration in contract development and manufacturing results in investment through takeover of 9.08% of shares via cash capital increase
Gross-proceeds in the amount of EUR 82.84 million to maintain Formyc [ … ]
Mon, 29.01.2024
Formycon AG
NOT FOR DISTRIBUTION, PUBLICATION OR TRANSMISSION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION, PUBLICATION OR TRANSMISSION WOULD BE UNLAWFUL. FURTHER RESTRICTIONS APPLY. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.
Disclosure of i [ … ]
Thu, 18.01.2024
Formycon AG
Press Release // January 18, 2024
Formycon Ranibizumab Biosimilar FYB201/CIMERLI® achieved a market share of 38% in the United States in December 2023
Munich, Germany – Formycon AG (FWB: FYB) today announced that its commercialization partner, Coherus BioSciences, Inc. has released new sales figures for CIMERLI®1 (Ranibizumab-eqrn) in the US [ … ]